| Women, n (%) |
8 (89) |
| Age (years, mean ± SD) |
56.6 ± 14.0 |
| Disease duration (years, mean ± SD) |
6 ± 5.7 |
| Raynaud phenomenon, n (%) |
6 (67) |
| Modified Rodnan total skin thickness score (mean ± SD) |
24.8 ± 7.9 |
| Organ involvement, n (%) |
|
| Digital ulcers |
3 (33) |
| Interstitial lung disease |
8 (89) |
| Pulmonary arterial hypertension |
1 (11) |
| Gastrointestinal involvement |
6 (67) |
| Autoantibodies, n (%) |
|
| Anti-topoisomerase I antibody |
2 (22) |
| Anti-RNA polymerase III antibody |
2 (22) |
| Anti-nuclear antibody |
2 (22) |
| Anti-SSA antibody |
2 (22) |
| Anticentromere antibody |
1 (11) |
| Treatment, n (%) |
|
| Corticosteroids (PSL < 10 mg/day) |
2 (22) |
| Mycophenolate mofetil |
1 (11) |
